ProPhase Labs, Inc. (NASDAQ: PRPH) Stock Competitors & Peer Comparison
See PRPH's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRPH and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRPH | $0.01 | -15.58% | 91.1K | N/A | -$3.01 | N/A |
| RPRX | $66.52 | -0.98% | 29.6B | 12.67 | $5.25 | +1.38% |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| CORT | $80.46 | -0.81% | 8.7B | 229.89 | $0.35 | N/A |
| KNSA | $90.80 | -1.56% | 7.1B | 69.77 | $1.30 | N/A |
| LQDA | $41.85 | -7.12% | 3.7B | 30.55 | $1.37 | N/A |
| PBH | $49.73 | +1.37% | 2.4B | 11.26 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $13.51 | -3.15% | 811.5M | -5.35 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
PRPH vs RPRX Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, RPRX has a market cap of 29.6B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while RPRX trades at $66.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas RPRX's P/E ratio is 12.67. In terms of profitability, PRPH's ROE is -13.59%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, PRPH is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check RPRX's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
PRPH vs WBA Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, PRPH's ROE is -13.59%, compared to WBA's ROE of -0.57%. Regarding short-term risk, PRPH is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check WBA's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
PRPH vs CORT Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, CORT has a market cap of 8.7B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while CORT trades at $80.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas CORT's P/E ratio is 229.89. In terms of profitability, PRPH's ROE is -13.59%, compared to CORT's ROE of +0.08%. Regarding short-term risk, PRPH is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CORT's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
PRPH vs KNSA Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, KNSA has a market cap of 7.1B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while KNSA trades at $90.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas KNSA's P/E ratio is 69.77. In terms of profitability, PRPH's ROE is -13.59%, compared to KNSA's ROE of +0.17%. Regarding short-term risk, PRPH is more volatile compared to KNSA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
PRPH vs LQDA Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, LQDA has a market cap of 3.7B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while LQDA trades at $41.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas LQDA's P/E ratio is 30.55. In terms of profitability, PRPH's ROE is -13.59%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, PRPH is more volatile compared to LQDA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
PRPH vs PBH Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while PBH trades at $49.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas PBH's P/E ratio is 11.26. In terms of profitability, PRPH's ROE is -13.59%, compared to PBH's ROE of +0.09%. Regarding short-term risk, PRPH is more volatile compared to PBH. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
PRPH vs HROWL Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, PRPH is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
PRPH vs HROWM Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas HROWM's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, PRPH is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
PRPH vs LTGO Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, LTGO has a market cap of 811.5M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while LTGO trades at $13.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas LTGO's P/E ratio is -5.35. In terms of profitability, PRPH's ROE is -13.59%, compared to LTGO's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to LTGO. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
PRPH vs HELP Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, HELP has a market cap of 545.5M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while HELP trades at $8.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas HELP's P/E ratio is -2.11. In terms of profitability, PRPH's ROE is -13.59%, compared to HELP's ROE of -0.71%. Regarding short-term risk, PRPH is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
PRPH vs SVA Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas SVA's P/E ratio is -5.68. In terms of profitability, PRPH's ROE is -13.59%, compared to SVA's ROE of -0.01%. Regarding short-term risk, PRPH is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SVA's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
PRPH vs CUVL Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, CUVL has a market cap of 249.9M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while CUVL trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas CUVL's P/E ratio is 10.68. In terms of profitability, PRPH's ROE is -13.59%, compared to CUVL's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CUVL's competition here
High Tide Inc. (NASDAQ: HITI)
PRPH vs HITI Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, HITI has a market cap of 230.9M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while HITI trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas HITI's P/E ratio is -9.57. In terms of profitability, PRPH's ROE is -13.59%, compared to HITI's ROE of -0.36%. Regarding short-term risk, PRPH is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check HITI's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
PRPH vs CELG-RI Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, CELG-RI has a market cap of 194.1M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, PRPH is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CELG-RI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
PRPH vs ETRA Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, ETRA has a market cap of 155.1M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while ETRA trades at $7.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas ETRA's P/E ratio is -2.76. In terms of profitability, PRPH's ROE is -13.59%, compared to ETRA's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to ETRA. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check ETRA's competition here
TRex Bio Inc. (NASDAQ: TRXB)
PRPH vs TRXB Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, TRXB has a market cap of 114.4M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while TRXB trades at $13.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas TRXB's P/E ratio is -5.56. In terms of profitability, PRPH's ROE is -13.59%, compared to TRXB's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to TRXB. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check TRXB's competition here
Atlantic International Corp. (NASDAQ: ATLN)
PRPH vs ATLN Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, ATLN has a market cap of 68.6M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas ATLN's P/E ratio is -0.68. In terms of profitability, PRPH's ROE is -13.59%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, PRPH is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check ATLN's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
PRPH vs CTOR Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, CTOR has a market cap of 55.2M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while CTOR trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas CTOR's P/E ratio is -1.26. In terms of profitability, PRPH's ROE is -13.59%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, PRPH is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check CTOR's competition here
Retension Pharmaceuticals Inc. (NASDAQ: RTSN)
PRPH vs RTSN Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, RTSN has a market cap of 43.6M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while RTSN trades at $11.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas RTSN's P/E ratio is -4.45. In terms of profitability, PRPH's ROE is -13.59%, compared to RTSN's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to RTSN. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check RTSN's competition here
Rite Aid Corporation (NYSE: RAD)
PRPH vs RAD Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, PRPH's ROE is -13.59%, compared to RAD's ROE of +2.76%. Regarding short-term risk, PRPH is more volatile compared to RAD. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
PRPH vs GLTO Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas GLTO's P/E ratio is -1.78. In terms of profitability, PRPH's ROE is -13.59%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, PRPH is more volatile compared to GLTO. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check GLTO's competition here
Cosmos Health Inc. (NASDAQ: COSM)
PRPH vs COSM Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, COSM has a market cap of 31.1M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while COSM trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.42. In terms of profitability, PRPH's ROE is -13.59%, compared to COSM's ROE of -1.19%. Regarding short-term risk, PRPH is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check COSM's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
PRPH vs NSRX Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, NSRX has a market cap of 27.6M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while NSRX trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas NSRX's P/E ratio is -4.44. In terms of profitability, PRPH's ROE is -13.59%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, PRPH is more volatile compared to NSRX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
PRPH vs SCYX Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, SCYX has a market cap of 24M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while SCYX trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.11. In terms of profitability, PRPH's ROE is -13.59%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, PRPH is more volatile compared to SCYX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SCYX's competition here
Pomdoctor Limited (NASDAQ: POM)
PRPH vs POM Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, POM has a market cap of 16.4M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while POM trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas POM's P/E ratio is -0.28. In terms of profitability, PRPH's ROE is -13.59%, compared to POM's ROE of +0.80%. Regarding short-term risk, PRPH is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check POM's competition here
Biofrontera Inc. (NASDAQ: BFRI)
PRPH vs BFRI Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, BFRI has a market cap of 13M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while BFRI trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -1.59. In terms of profitability, PRPH's ROE is -13.59%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, PRPH is more volatile compared to BFRI. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BFRI's competition here
Cerenome, Inc. (NASDAQ: CNSY)
PRPH vs CNSY Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, CNSY has a market cap of 12.9M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while CNSY trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas CNSY's P/E ratio is -0.41. In terms of profitability, PRPH's ROE is -13.59%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, PRPH is more volatile compared to CNSY. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CNSY's competition here
Azora Therapeutics, Inc. (NASDAQ: AZR)
PRPH vs AZR Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, AZR has a market cap of 10.4M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while AZR trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas AZR's P/E ratio is -0.24. In terms of profitability, PRPH's ROE is -13.59%, compared to AZR's ROE of N/A. Regarding short-term risk, PRPH is less volatile compared to AZR. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check AZR's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
PRPH vs CJJD Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, PRPH's ROE is -13.59%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, PRPH is more volatile compared to CJJD. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
PRPH vs SSY Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, PRPH's ROE is -13.59%, compared to SSY's ROE of -0.09%. Regarding short-term risk, PRPH is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
PRPH vs SCNX Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, SCNX has a market cap of 5.3M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while SCNX trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas SCNX's P/E ratio is -1.54. In terms of profitability, PRPH's ROE is -13.59%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, PRPH is more volatile compared to SCNX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SCNX's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
PRPH vs BGMS Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, BGMS has a market cap of 5M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while BGMS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.25. In terms of profitability, PRPH's ROE is -13.59%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, PRPH is more volatile compared to BGMS. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BGMS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
PRPH vs MDVL Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, PRPH's ROE is -13.59%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, PRPH is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check MDVL's competition here
Eocene Ltd. (NASDAQ: EOCN)
PRPH vs EOCN Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, EOCN has a market cap of 2.8M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while EOCN trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas EOCN's P/E ratio is -0.19. In terms of profitability, PRPH's ROE is -13.59%, compared to EOCN's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to EOCN. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
PRPH vs PAVS Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, PAVS has a market cap of 2.7M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while PAVS trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas PAVS's P/E ratio is -0.03. In terms of profitability, PRPH's ROE is -13.59%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, PRPH is more volatile compared to PAVS. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check PAVS's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
PRPH vs ATNFW Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, PRPH is more volatile compared to ATNFW. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
PRPH vs BGMSP Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, PRPH's ROE is -13.59%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, PRPH is more volatile compared to BGMSP. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
PRPH vs AZNH Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, PRPH's ROE is -13.59%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, PRPH is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check AZNH's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP)
PRPH vs ASBP Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, ASBP has a market cap of 842.2K. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while ASBP trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas ASBP's P/E ratio is -0.31. In terms of profitability, PRPH's ROE is -13.59%, compared to ASBP's ROE of +19.93%. Regarding short-term risk, PRPH is more volatile compared to ASBP. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check ASBP's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
PRPH vs BFRIW Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, BFRIW has a market cap of 796.7K. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while BFRIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, PRPH is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check BFRIW's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
PRPH vs LFLYW Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, PRPH's ROE is -13.59%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, PRPH is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check LFLYW's competition here
Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW)
PRPH vs ASBPW Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, ASBPW has a market cap of 149.5K. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while ASBPW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas ASBPW's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to ASBPW's ROE of +19.93%. Regarding short-term risk, PRPH is less volatile compared to ASBPW. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check ASBPW's competition here
POZEN Inc. (NASDAQ: POZN)
PRPH vs POZN Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, POZN has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to POZN's ROE of +0.61%. Regarding short-term risk, PRPH is more volatile compared to POZN. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check POZN's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
PRPH vs CPD Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, CPD has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, PRPH's ROE is -13.59%, compared to CPD's ROE of N/A. Regarding short-term risk, PRPH is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
PRPH vs SHPG Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, SHPG has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is 11.35. In terms of profitability, PRPH's ROE is -13.59%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, PRPH is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check SHPG's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
PRPH vs OREX Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, OREX has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas OREX's P/E ratio is -0.14. In terms of profitability, PRPH's ROE is -13.59%, compared to OREX's ROE of -0.54%. Regarding short-term risk, PRPH is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for PRPH.Check OREX's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
PRPH vs ESRX Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, ESRX has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is 10.69. In terms of profitability, PRPH's ROE is -13.59%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, PRPH is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
PRPH vs IPXL Comparison November 2026
ProPhase Labs, Inc. (NASDAQ: PRPH) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRPH stands at 91.1K. In comparison, IPXL has a market cap of 0. Regarding current trading prices, PRPH is priced at $0.01 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRPH currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is -10.11. In terms of profitability, PRPH's ROE is -13.59%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, PRPH is more volatile compared to IPXL. This indicates higher risk in terms of short-term price fluctuations for PRPH.Check IPXL's competition here